Published on 4 Sep 2023 on Simply Wall St. via Yahoo Finance

Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. The US$148m market-cap company posted a loss in its most recent financial year of US$34m and a latest trailing-twelve-month loss of US$31m shrinking the gap between loss and breakeven. As path to profitability is the topic on Citius Pharmaceuticals' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

See our latest analysis for Citius Pharmaceuticals

According to the 3 industry analysts covering Citius Pharmaceuticals, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$45m in 2025. The company is therefore projected to breakeven around 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 69% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.